Inhibition of the HER2 tyrosine kinase and characterization of a hydrophobic site near the nucleotide binding domain

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 16, 1997, Pages 2109-2114

  Maddry, Joseph A ^a   Kussner, Conrad ^a   Truss, Jackie W ^a   Niwas, Shri ^a   White, E Lucile ^a   Kwong, Cecil D ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; BINDING SITE; CHEMICAL MODIFICATION; DRUG SYNTHESIS; HUMAN; HYDROPHOBICITY; RECEPTOR BINDING;

EID: 0030762373     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00369-7     Document Type: Article

References (54)

1. th Annual Meeting of The American Association for Cancer Research, Washington, D. C., April 20-24,1996, Abstract No. 2006.
2. (a) Burke, Jr., T. R. Stem Cells 1994, 12, 1;
3. (b) Fantl, W. J.; Johnson, D. E.; Williams, L. T. Annu. Rev. Biochem. 1993, 62, 453;
4. (c) Foster, D. A. Cell. Signal. 1993, 5, 389;
5. (d) Hunter, T.; Lindberg, R. A.; Middlemas, D. S.; Tracy, S.; van der Geer, P. Cold Spring Harbor Symposia on Quantitative Biology 1992, 25;
6. (e) Schlessinger, J.; Ullrich, A. Neuron 1992, 9, 383;
7. (f) Ullrich, A.; Schlessinger, J. Cell 1990, 61, 203;
8. (g) Yarden, Y.; Ullrich, A. Annu. Rev. Biochem. 1988, 57, 443.
9. Brindt-Rauf, P. W.; Pincus, M.R.; Carney, W. P. Crit. Rev. Oncogenesis 1994, 5, 313.
10. Jardines, L.; Weiss, M.; Fowble, B.; Greene, M. Pathobiology 1993, 61, 268.
11. Peles, E.; Yarden, Y. Bioessays 1993, 75, 815.
12. (a) Gullick, W. J. Canc. Surveys 1996, 27, 339;
13. (b) Simpson, B. J. B.; Weatherill, J.; Miller, E. P.; Lessells, A. M.; Langdon, S. P.; Miller, W. R. Brit. J. Canc. 1995, 71, 758;
14. (c) Modjtahedi, H.; Dean, C. Int. J. Oncol. 1994, 4, 277;
15. (d) Culouscou, J.-M.; Plowman, G. D.; Carlton, G. W.; Green, J. M.; Shoyab, M. J. Biol. Chem. 1993, 268, 18407;
16. (e) Khazaie, K.; Schirrmacher, V.; Lichtner, R. B. Canc. Metast. Rev. 1993, 12, 255;
17. (f) Dougall, W. C.; Qian, X.; Greene, M. I. J. Cell. Biochem. 1993, 53, 61.
18. (a) Levitzski, A.; Gazit, A. Science 1995, 267, 1782;
19. (b) He, H.-M.; Geahlen, R. L.; Cushman, M. Bioorg. Med. Chem. Lett. 1994, 4, 1729;
20. (c) Dow, R. L.; Chou, T. T.; Bechle, B. M.; Goddard, C.; Larson, E. R. J. Med. Chem. 1994, 37, 2224;
21. (d) Groundwater, P. W.; Solomons, K. R. H. J. Chem. Soc. Perkin Trans. 1 1994, 173;
22. (e) Fry, D. W.; Kraker, A. J.; Connors, R. C.; Elliott, W. L.; Nelson, J. M.; Showalter, H. D. H.; Leopold, W. R. Anti-Canc. Drug Design 1994, 9, 331;
23. (f) Buzzetti, F.; Brasca, M. G.; Crugnola, A.; Fustinoni, S.; Longo, A.; Penco, S.; Zonca, P. D.; Comoglio, P. M. Il Farmaco 1993, 48, 615;
24. (g) Burke, Jr., T. R.; Lim, B.; Marquez, V. E.; Li, Z.-H.; Bolen, J. B.; Stefanova, I.; Horak, I. D. J. Med. Chem. 1993, 36, 425;
25. (h) Smyth, M. S.; Stefanova, I.; Horak, I. D.Burke, Jr., T. R. J. Med. Chem. 1993, 36, 3015;
26. (i) Thakker, K.; Geahlen, R. L.; Cushman, M. J. Med. Chem. 1993, 36, 2950;
27. (j) Smyth, M. S.; Stefanova, I.; Hartmann, F.; Horak, I. D.; Osherov, N.; Levitzki, A.; Burke, Jr., T. R. J. Med. Chem. 1993, 36, 3010;
28. (k) Burke, Jr., T. R. Drugs of the Future 1992, 17, 119.
29. (a) Singh, J.; Dobrusin, E. M.; Fry, D. W.; Haske, T.; Whitty, A.; McNamara, D. J. J. Med. Chem. 1997, 40, 1130;
30. (b) Hegde, V. R.; Dai, P.; Patel, M.; Das, P. R.; Puar, M. S. Tetrahedron Lett. 1997, 38, 911;
31. (c) Liu, T.; Shirai, R.; Matsui, T.; Umezawa, K.; Iwasaki, S. Bioorg. Med. Chem. Lett. 1997, 7, 365;
32. (d) Showalter, H. D. H.; Sercel, A. D.; Leja, B. M.; Wolfangel, C. D.; Ambroso, L. A.; Elliott, W. L.; Fry, D. W.; Kraker, A. J.; Howard, C. T.; Lu, G. H.; Moore, C. W.; Nelson, J. M.; Roberts, B. J.; Vincent, P. W.; Denny, W. A.; Thompson, A. M. J. Med. Chem. 1997, 40, 413;
33. (e) Gazit, A.; Chen, J.; App, H.; McMahon, G.; Hirth, P.; Chen, I.; Levitzki, A. Bioorg. Med. Chem. 1996, 4, 1203;
34. (f) Gazit, A.; Osherov, N.; Gilon, C.; Levitzki, A. J. Med. Chem. 1996, 39, 4905;
35. (g) Palmer, B. D.; Rewcastle, G. W.; Thompson, A. M.; Boyd, M.; Showalter, H. D. H.; Sercel, A. D.; Fry, D. W.; Kraker, A. J.; Denny, W. A. J. Med. Chem. 1995, 35, 58;
36. (h) Thompson, A. M.; Fry, D. W.; Kraker, A. J.; Denny, W. A. J. Med Chem. 1994, 37, 598;
37. (i) Trinks, U.; Buchdunger, E.; Furet, P.; Kump, W.; Mett, H.; Meyer, T.; Müller, M.; Regenass, U.; Rihs, G.; Lydon, N.; Traxler, P. J. Med Chem. 1994, 37, 1015;
38. (j) Chen, H.; Boiziau, J.; Parker, F.; Mailliet, P.; Commerçon, A.; Tocque, B.; Le Pecq, J.-B.; Roques, B.-P.; Garbay, C. J. Med. Chem. 1994, 37, 845.
39. Peterli, S.; Stumpf, R.; Schweizer, M.; Séquin, U.; Mett, H.; Traxler, P. Helv. Chim. Acta 1992, 75, 696.
40. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambrosoe, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. Science 1994, 265, 1093.
41. Pinkas-Kramarski, R.; Shelly, M.; Glathe, S.; Ratzkin, B. J.; Yarden, Y. J. Biol. Chem. 1996, 271, 19029.
42. (a) Reese, D. M.; Slamon, D. J. Stem Cells 1997, 75, 1;
43. (b) Ohnishi, Y.; Nakamura, H.; Yoshimura, M.; Tokuda, Y.; Iwasawa, M.; Ueyama, Y.; Tamaoki, N.; Shimamura, K. Brit. J. Canc. 1995, 71, 969;
44. (c) Singleton, T. P.; Perrone, T.; Oakley, G.; Niehans, G. A.; Carson, L.; Cha, S. S.; Strickler, J. G. Cancer 1994, 73, 1460;
45. (d) Pastan, I. Jap. J. Canc. Res. 1993, 84, 1336;
46. (e) Giri, D. K.; Wadhwa, S. N.; Upadhaya, S. N.; Talwar, G. P. Prostate 1993, 23, 329.
47. 9 (published data for the HER2 TK were unavailable).
48. Cohen, N. C.; Blaney, J. M.; Humblet, C.; Gund, P.; Barry, D. C. J. Med. Chem. 1990, 33, 883.
49. Montgomery, J. A.; Niwas, S.; Rose, J. D.; Secrist III, J. A.; Babu, Y. S.; Bugg, C. E.; Erion, M. D.; Guida, W. C.; Ealick, S. E. J. Med. Chem. 1993, 36, 55.
50. 5 to yield the desired product (4.16 g, 94%). The material was used without further purification, though an aliquot was recrystallized from boiling water for characterization.
51. 3 eluant), yielding 0.377 g analytically pure 6j.
52. 2C=O).
53. Levitzki, A.; Gazit, A.; Osherov, N.; Posner, I.; Gilon, C. Methods Enzymol. 1991, 201, 347.
54. Osherov, N.; Gazit, A.; Gilon, C.; Levitzki, A. J. Biol. Chem. 1993, 268, 11134.